OBJECTIVE: The plasminogen activator system (PA) plays an important role in invasion and metastasis of solid tumors. The PA Inhibitor type 1 (PAI-1) is the main physiologic regulator of plasminogen activation. A recently characterized protein, PAI-RBP1 (PAI-1 mRNA Binding Protein 1), appears to regulate the stability of PAI-1 mRNA. Expression of PAI-RBP1 (the new, approved gene symbol is SERBP1) has not been previously analyzed in human tumors. We present herein for the first time expression analysis of PAI-RBP1 in epithelial ovarian cancer. METHODS: PAI-RBP1 was identified as gene overexpressed in ovarian cancer by an in silico approach using EST database mining. A thorough expression analysis of PAI-RBP1 and PAI-1 was performed in normal ovary (n=4), benign (n=6) and malignant (n=42) ovarian lesions using non-radioactive RNA in situ hybridization and immunohistochemistry, respectively. RESULTS: PAI-RBP1 mRNA and PAI-1 were significantly overexpressed in tumor epithelial cells as compared to benign and normal ovarian tissue. A significant correlation between PAI-RBP1 expression and advanced disease stage (FIGO) was found (p=0.042). CONCLUSION: In ovarian cancer, PAI-RBP1 is significantly overexpressed in tumor epithelial cells, suggesting a biological role in tumor invasion and metastasis. Its expression is higher in advanced disease, thus the prognostic significance of PAI-RBP1 in ovarian cancer remains to be evaluated in further studies.
OBJECTIVE: The plasminogen activator system (PA) plays an important role in invasion and metastasis of solid tumors. The PA Inhibitor type 1 (PAI-1) is the main physiologic regulator of plasminogen activation. A recently characterized protein, PAI-RBP1 (PAI-1 mRNA Binding Protein 1), appears to regulate the stability of PAI-1 mRNA. Expression of PAI-RBP1 (the new, approved gene symbol is SERBP1) has not been previously analyzed in humantumors. We present herein for the first time expression analysis of PAI-RBP1 in epithelial ovarian cancer. METHODS:PAI-RBP1 was identified as gene overexpressed in ovarian cancer by an in silico approach using EST database mining. A thorough expression analysis of PAI-RBP1 and PAI-1 was performed in normal ovary (n=4), benign (n=6) and malignant (n=42) ovarian lesions using non-radioactive RNA in situ hybridization and immunohistochemistry, respectively. RESULTS:PAI-RBP1 mRNA and PAI-1 were significantly overexpressed in tumor epithelial cells as compared to benign and normal ovarian tissue. A significant correlation between PAI-RBP1 expression and advanced disease stage (FIGO) was found (p=0.042). CONCLUSION: In ovarian cancer, PAI-RBP1 is significantly overexpressed in tumor epithelial cells, suggesting a biological role in tumor invasion and metastasis. Its expression is higher in advanced disease, thus the prognostic significance of PAI-RBP1 in ovarian cancer remains to be evaluated in further studies.
Authors: Yelenis Mari; Graham M West; Catherina Scharager-Tapia; Bruce D Pascal; Ruben D Garcia-Ordonez; Patrick R Griffin Journal: J Proteome Res Date: 2015-10-07 Impact factor: 4.466
Authors: Ovidiu Marina; Ursula Hainz; Melinda A Biernacki; Wandi Zhang; Ann Cai; Jonathan S Duke-Cohan; Fenglong Liu; Vladimir Brusic; Donna Neuberg; Jeffery L Kutok; Edwin P Alyea; Christine M Canning; Robert J Soiffer; Jerome Ritz; Catherine J Wu Journal: Cancer Res Date: 2010-02-02 Impact factor: 12.701
Authors: Laurie A Davidson; Naisyin Wang; Manasvi S Shah; Joanne R Lupton; Ivan Ivanov; Robert S Chapkin Journal: Carcinogenesis Date: 2009-12 Impact factor: 4.944
Authors: Sasha E Stanton; Ekram Gad; Erik Ramos; Lauren Corulli; James Annis; Jennifer Childs; Hiroyuki Katayama; Samir Hanash; Jeffrey Marks; Mary L Disis Journal: NPJ Breast Cancer Date: 2021-05-11
Authors: Nuran Bektas Serce; Andreas Boesl; Irina Klaman; Sonja von Serényi; Erik Noetzel; Michael F Press; Arno Dimmler; Arndt Hartmann; Jalid Sehouli; Ruth Knuechel; Matthias W Beckmann; Peter A Fasching; Edgar Dahl Journal: BMC Cancer Date: 2012-12-13 Impact factor: 4.430